home / stock / cybn:cc / cybn:cc news

CYBN:CC News and Press, CYBIN INC. From 06/29/23

Stock Information
Company Name: CYBIN INC.
Stock Symbol: CYBN:CC
Market: AQNC
Menu
CYBN:CC CYBN:CC Quote CYBN:CC Short CYBN:CC News CYBN:CC Articles CYBN:CC Message Board
Get CYBN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
CYBN:CC - Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer

This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplement dated August 8, 2022 and prospectus supplement dated May 30, 2023 to its short form base shelf prospectus dated July 5, 2021 Cybin Inc. (NEO:CYBN) (NYSE A...
CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases FY 2023 Financial Report, Business Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on its audited financial results for the fiscal year ended March 31, 2023. Hi...

CYBN:CC - Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights

- Initiated First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial - - Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004 1,2 - - U.S. Food and Drug Administration (“FDA”) submission o...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names Seasoned Veteran as Strategic Advisor

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has appointed Sanford R. Climan as a strategic advisor. The CEO and founder of Entertainme...
CYBN:CC - Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce t...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Psychedelic Science 2023 Conference

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company has announced that its Chief Executive Officer Doug Drysdale and SVP of Clinical...

CYBN:CC - Cybin to Participate in the 2023 MAPS Psychedelic Science Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce t...
CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Upcoming H.C. Wainwright Neuropsychiatry Conference

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that its Chief Executive Officer Doug Drysdale will participate ...

CYBN:CC - Cybin to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce t...

CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Report on Status of Capital, Product Development

Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on its capital and upcoming clinical milestones. As part of the report, the c...
Previous 10 Next 10